Characteristics of patient groups and disease controls
| Active systemic AAV | Follow-up (12 months) | LGD | IgA nephropathy | |
|---|---|---|---|---|
| No of subjects | 24 | 19 | 6 | 20 |
| Sex (male/female) | 9/15 | 8/11 | 4/2 | 10/10 |
| Age (years) | 53±16 | 54±15 | 59±15 | 45±9 |
| BMI (kg/m2) | 25±4.3 | 23.8±4.3 | 24.3±4.9 | 25.7±3.2 |
| S-creatinine (μmol/l) | 219.5±137.4 | 147.8±166.9 | 95.7±28.6 | 300.3±155.7 |
| eGFR (ml/min) | 42.3±27.6 | 62.9±25.7 | 72.8±21.8 | 42.5±39 |
| CRP (mg/l) | 62.7±82 | 10.8±20.6 | 8.8±14.3 | 1 |
| BVAS | 17.9±9.3 | 0.7±2 | 3±3.3 | NA |
| MPA/WG | 6/18 | 4/15 | 0/6 | NA |
AAV, antineutrophil cytoplasmic autoantibody-associated vasculitis; BMI, body mass index; BVAS, Birmingham vasculit is activity score; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate (MDRD formula); LGD, limited granulomatous disease; MPA, microscopic polyangitis; NA, not applicable; WG, Wegener's granulomatosis.